Cited by 2,561Schizophrenia research and treatmentMental Health and PsychiatryTreatment of Major Depression

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

Leucht, Stefan, Cipriani, Andrea, Spineli, Loukia, Mavridis, Dimitris, Örey, Deniz, Richter, Franziska, Samara, Myrto, Barbui, Corrado, Engel, Rolf R, Geddes, John R, Kissling, Werner, Stapf, Marko Paul, Lässig, Bettina, Salanti, Georgia, Davis, John M·2013·The Lancet

DOI 10.1016/s0140-6736(13)60733-3

Open this paper in CoChat — free account

Abstract

Background The question of which antipsychotic drug should be preferred for the treatment of schizophrenia is controversial, and conventional pairwise meta-analyses cannot provide a hierarchy based on the randomised evidence. We aimed to integrate the available evidence to create hierarchies of the comparative efficacy, risk of all-cause discontinuation, and major side-effects of antipsychotic drugs.Methods We did a Bayesian-framework, multiple-treatments meta-analysis (which uses both direct and indirect comparisons) of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia. We searched the Cochrane Schizophrenia Group's specialised register, Medline, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for reports published up to Sept 1, 2012. Search results were supplemented by reports from the US Food and Drug Administration website and by data requested from pharmaceutical companies. Blinded, randomised controlled trials of patients with schizophrenia or related disorders were eligible. We excluded trials done in patients with predominant negative symptoms, concomitant medical illness, or treatment resistance, and those done in stable patients. Data for seven outcomes were independently extracted by two reviewers. The primary outcome was efficacy, as measured by mean overall change in symptoms. We also examined all-cause discontinuation, weight gain, extrapyramidal side-effects, prolactin increase, QTc prolongation, and sedation.Findings We identified 212 suitable trials, with data for 43 049 participants. All drugs were significantly more effective than placebo. The standardised mean differences with 95% credible intervals were: clozapine 0·88, 0·73-1·03; amisulpride 0·66, 0·53-0·78; olanzapine 0·59, 0·53-0·65; risperidone 0·56, 0·50-0·63; paliperidone 0·50, 0·39-0·60; zotepine 0·49, 0·31-0·66; haloperidol 0·45, 0·39-0·51; quetiapine 0·44, 0·35-0·52; aripiprazole 0·43, 0·34-0·52; sertindole 0·39, 0·26-0·52; ziprasidone 0·39, 0·30-0·49; chlorpromazine 0·38, 0·23-0·54; asenapine 0·38, 0·25-0·51; lurasidone 0·33, 0·21-0·45; and iloperidone 0·33, 0·22-0·43. Odds ratios compared with placebo for all-cause discontinuation ranged from 0·43 for the best drug (amisulpride) to 0·80 for the worst drug (haloperidol); for extrapyramidal side-effects 0·30 (clozapine) to 4·76 (haloperidol); and for sedation 1·42 (amisulpride) to 8·82 (clozapine). Standardised mean differences compared with placebo for weight gain varied from -0·09 for the best drug (haloperidol) to -0·74 for the worst drug (olanzapine), for prolactin increase 0·22 (aripiprazole) to -1·30 (paliperidone), and for QTc prolongation 0·10 (lurasidone) to -0·90 (sertindole). Efficacy outcomes did not change substantially after removal of placebo or haloperidol groups, or when dose, percentage of withdrawals, extent of blinding, pharmaceutical industry sponsorship, study duration, chronicity, and year of publication were accounted for in meta-regressions and sensitivity analyses.Interpretation Antipsychotics differed substantially in side-effects, and small but robust differences were seen in efficacy. Our findings challenge the straightforward classification of antipsychotics into first-generation and second-generation groupings. Rather, hierarchies in the different domains should help clinicians to adapt the choice of antipsychotic drug to the needs of individual patients. These findings should be considered by mental health policy makers and in the revision of clinical practice guidelines.Funding None.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(13)60733-3

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Statistical Power Analysis for the Behavioral Sciences
Muller, K. E., & Cohen, J. (1989) · Technometrics · doi:10.2307/1270020 · Cited by 99,603
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,417
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J., Green, S. R., & Higgins, J. (2008) · Cited by 5,544
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
Salanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766
Self-citation
Checking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521

Show all 61 references

Research works printed but not linked: 1

Leucht, 2009, A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia, Am J Psychiatry, 166, 152, 10.1176/appi.ajp.2008.08030368 · DOI

Sorted by citations

Items 601–700 of 1,006

Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates
Cunningham, J. I., Eyerman, D. J., Todtenkopf, M. S., Dean, R. L., Deaver, D. R., Sánchez, C., & Namchuk, M. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119856850 · Cited by 33
Neurocognitive and neurophysiological endophenotypes in schizophrenia: An overview
Donati, F. L., D’Agostino, A., & Ferrarelli, F. (2020) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2020.100017 · Cited by 33
Schizophrenia spectrum and other psychotic disorders
Lewine, R. J., & Hart, M. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64123-6.00022-9 · Cited by 35
Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia
Correll, C. U., Vanover, K. E., Davis, R. E., Chen, R., Satlin, A., & Mates, S. L. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.12.006 · Cited by 33
Clinical pharmacist interventions in cardiovascular disease pharmacotherapy in elderly patients on excessive polypharmacy
Štuhec, M., Flegar, I., Zelko, E., Kovačič, A., & Zabavnik, V. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-020-01801-y · Cited by 33
Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the “real-life”
Monteleone, P., Cascino, G., Monteleone, A. M., Rocca, P., Rossi, A., Bertolino, A., Aguglia, E., Amore, M., Collantoni, E., Corrivetti, G., et al. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110250 · Cited by 32
Recent advances in dopamine D 2 receptor ligands in the treatment of neuropsychiatric disorders
Jůza, R., Musílek, K., Mezeiová, E., Soukup, O., & Korábečný, J. (2022) · Medicinal Research Reviews · doi:10.1002/med.21923 · Cited by 34
Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia
Qubad, M., & Bittner, R. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231158152 · Cited by 33
A systematic review on sex differences in adverse drug reactions related to psychotropic, cardiovascular, and analgesic medications
Shan, Y., Cheung, L., Zhou, Y., Huang, Y., & Huang, R. S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1096366 · Cited by 32
Precision psychiatry: predicting predictability
van Dellen, E. (2024) · Psychological Medicine · doi:10.1017/s0033291724000370 · Cited by 45
A review on schizophrenia and relapse—a quest for user‐friendly psychopharmacotherapy
Suzuki, T., Uchida, H., Takeuchi, H., Tsuboi, T., Hirano, J., & Mimura, M. (2014) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2421 · Cited by 32
Olanzapine-depot administration induces time-dependent changes in adipose tissue endocrine function in rats
Horská, K., Kučerová, J., Babinská, Z., Karpíšek, M., Demlová, R., Opatřilová, R., Suchý, P., & Kotolová, H. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.07.218 · Cited by 33
Effects of antipsychotics on intestinal motility in zebrafish larvae
de Alvarenga, K. A. F., Sacramento, E. K., Rosa, D. V., Souza, B. R., de Rezende, V. B., & Romano‐Silva, M. A. (2016) · Neurogastroenterology & Motility · doi:10.1111/nmo.13006 · Cited by 32
Efficacy, acceptability and tolerability of 8 atypical antipsychotics in Chinese patients with acute schizophrenia: A network meta-analysis
Bai, Z., Wang, G., Cai, S., Ding, X., Liu, W., Huang, D., Shen, W., Zhang, J., Chen, K., Yang, Y., et al. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.01.002 · Cited by 32
Functionally Biased D2R Antagonists: Targeting the β-Arrestin Pathway to Improve Antipsychotic Treatment
Weïwer, M., Xu, Q., Gale, J. P., Lewis, M., Campbell, A. J., Schroeder, F. A., de Bittner, G. C. V., Walk, M., Amaya, A., Su, P., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00168 · Cited by 32
Evidence-Based Review Of Pharmacotherapy For Acute Agitation. Part 2: Safety
Zun, L. S. (2018) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2017.11.031 · Cited by 32
Relation of inflammatory markers with symptoms of psychotic disorders: a large cohort study
Liemburg, E. J., Nolte, I. M., Klein, H. C., & Knegtering, H. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.04.006 · Cited by 32
Weight gain and metabolic change as predictors of symptom improvement in first-episode schizophrenia spectrum disorder patients treated over 12 months
Luckhoff, H. K., Phahladira, L., Scheffler, F., Asmal, L., du Plessis, S., Chiliza, B., Kilian, S., & Emsley, R. A. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.11.031 · Cited by 33
Point-of-care measurement of clozapine concentration using a finger-stick blood sample
Taylor, D. M., Atkins, M., Harland, R., Baburina, I., MacCabe, J. H., Salamone, S. J., & McGuire, P. K. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121991567 · Cited by 32
The Role of Board-Certified Psychiatric Pharmacists in Expanding Access to Care and Improving Patient Outcomes
Goldstone, L. W., DiPaula, B. A., Werremeyer, A. B., Botts, S. R., Hepburn, B. M., Liu, H. Y., Duckworth, K., Young, A. S., & Kelly, D. L. (2021) · Psychiatric Services · doi:10.1176/appi.ps.202000066 · Cited by 32
Immune activation in lactating dams alters sucklings' brain cytokines and produces non-overlapping behavioral deficits in adult female and male offspring: A novel neurodevelopmental model of sex-specific psychopathology
Arad, M., Piontkewitz, Y., Albelda, N., Shaashua, L., & Weiner, I. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.01.015 · Cited by 33
Clozapine use in geriatric patients— Challenges
Mukku, S. S. R., Sivakumar, P. T., & Varghese, M. (2018) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2018.03.008 · Cited by 32
Risperidone and Risk of Gynecomastia in Young Men
Etminan, M., Carleton, B., & Brophy, J. M. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0024 · Cited by 31
Weight and body mass index increase in children and adolescents exposed to antipsychotic drugs in non-interventional settings: a meta-analysis and meta-regression
Pozzi, M., Ferrentino, R. I., Scrinzi, G., Scavone, C., Capuano, A., Radice, S., Nobile, M., Formisano, P., Clementi, E., Bravaccio, C., et al. (2020) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-020-01582-9 · Cited by 31
Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review
Solmi, M., Miola, A., Capone, F., Pallottino, S., Højlund, M., Firth, J., Siskind, D. J., Holt, R. I. G., Corbeil, O., Cortese, S., et al. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2396396 · Cited by 35
Chlorpromazine versus every other antipsychotic for schizophrenia: A systematic review and meta-analysis challenging the dogma of equal efficacy of antipsychotic drugs
Samara, M. T., Cao, H., Helfer, B., Davis, J. M., & Leucht, S. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.012 · Cited by 34
Self-citation
Managing cardiovascular disease risk in patients treated with antipsychotics: a multidisciplinary approach
Shulman, M., Miller, A., Misher, J., & Tentler, A. (2014) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s49817 · Cited by 30
Detecting and Managing Adverse Effects of Antipsychotic Medications
Ames, D., Carr‐Lopez, S. M., Gutierrez, M. A., Pierre, J. M., Rosen, J. A., Shakib, S., & Yudofsky, L. M. (2016) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2016.01.008 · Cited by 33
Tachycardia in patients treated with clozapine versus antipsychotic long-acting injections
Nilsson, B. M., Edström, O., Lindström, L., Wernegren, P., & Bodén, R. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000169 · Cited by 29
Investigating the link between drug-naive first episode psychoses (FEPs), weight gain abnormalities and brain structural damages: Relevance and implications for therapy
Minichino, A., Ando, A. M. C., Francesconi, M., Salatino, A., Chiaie, R. D., & Cadenhead, K. S. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.03.020 · Cited by 32
Orexin-A Levels in Relation to the Risk of Metabolic Syndrome in Patients with Schizophrenia Taking Antipsychotics
Chen, P., Chen, C.-H., Chang, C., Kao, C.-F., Lu, M., Lin, S., Huang, M., Hwang, L.-L., & Mondelli, V. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy075 · Cited by 31
The differential actions of clozapine and other antipsychotic drugs on the translocation of dopamine D2 receptors to the cell surface
Schrader, J. M., Irving, C. M., Octeau, J. C., Christian, J. A., Aballo, T. J., Kareemo, D. J., Conti, J., Camberg, J. L., Lane, J. R., Javitch, J. A., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004682 · Cited by 31
An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes
Zhang, C., Yuan, Y., Han, X., Yang, L., Cai, S., Yang, F., Lu, Z., Wang, C., Deng, H., Zhao, J., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119872193 · Cited by 31
Can N-Methyl-D-Aspartate Receptor Hypofunction in Schizophrenia Be Localized to an Individual Cell Type?
Bygrave, A. M., Kilonzo, K., Kullmann, D. M., Bannerman, D. M., & Kätzel, D. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00835 · Cited by 35
Distinct striatum pathways connected to salience network predict symptoms improvement and resilient functioning in schizophrenia following risperidone monotherapy
Han, S., Becker, B., Duan, X., Cui, Q., Xin, F., Zong, X., Hu, M., Yang, M., Li, R., Yu, Y., et al. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.11.017 · Cited by 33
Orexin receptor antagonists reverse aberrant dopamine neuron activity and related behaviors in a rodent model of stress-induced psychosis
Reiley, H. B., Perez, S. M., Donegan, J. J., & Lodge, D. J. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01235-8 · Cited by 32
Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: Analysis of the CATIE phase 2E data
Nakajima, S., Takeuchi, H., Fervaha, G., Plitman, E., Chung, J. K., Caravaggio, F., Iwata, Y., Mihashi, Y., Gerretsen, P., Remington, G. J., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.12.024 · Cited by 33
Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: a cost-effectiveness analysis
Girardin, F., Poncet, A., Blondon, M., Rollason, V., Vernaz, N., Chalandon, Y., Dayer, P., & Combescure, C. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)70245-7 · Cited by 32
Facial affect processing deficits in schizophrenia: A meta-analysis of antipsychotic treatment effects
Gabay, A. S., Kempton, M. J., & Mehta, M. A. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114560184 · Cited by 38
Increasing antipsychotic dose for non response in schizophrenia
Samara, M. T., Klupp, E., Helfer, B., Rothe, P., Schneider‐Thoma, J., & Leucht, S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011883.pub2 · Cited by 30
Self-citation
Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis
Siskind, D. J., Harris, M., Phillipou, A., Morgan, V. A., Waterreus, A. J., Galletly, C. A., Carr, V. J., Harvey, C. A., & Castle, D. J. (2016) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796016000305 · Cited by 31
Quantitative and systems pharmacology 2. In silico polypharmacology of G protein-coupled receptor ligands via network-based approaches
Wu, Z., Lü, W., Yu, W., Wang, T., Li, W., Liu, G., Zhang, H., Pang, X., Huang, J. Y., Liu, M., et al. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.005 · Cited by 31
High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine
Larsen, J. R., Svensson, C. K., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. S. R., Jakobsen, M. I., Koyuncu, K., Schjerning, O., Nielsen, J., Ekstrøm, C. T., et al. (2018) · CNS Spectrums · doi:10.1017/s1092852918001311 · Cited by 32
Brexpiprazole: A Review in Schizophrenia
Garnock-Jones, K. P. (2016) · CNS Drugs · doi:10.1007/s40263-016-0325-8 · Cited by 30
The potential effect of metformin on cognitive and other symptom dimensions in patients with schizophrenia and antipsychotic-induced weight gain: a systematic review, meta-analysis, and meta-regression
Battini, V., Cirnigliaro, G., Leuzzi, R., Rissotto, E., Mosini, G., Benatti, B., Pozzi, M., Nobile, M., Radice, S., Carnovale, C., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1215807 · Cited by 29
Weighing the evidence for harm from long-term treatment with antipsychotic medications: A systematic review.
Sohler, N., Adams, B. G., Barnes, D. M., Cohen, G. H., Prins, S. J., & Schwartz, S. (2015) · American Journal of Orthopsychiatry · doi:10.1037/ort0000106 · Cited by 30
Lurasidone for the treatment of bipolar depression: an evidence-based review
Deckersbach, T., Widge, A. S., Franklin, R., Zorowitz, S., & Corse, A. K. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s50961 · Cited by 32
Clozapine use and sedentary lifestyle as determinants of metabolic syndrome in outpatients with schizophrenia
Eskelinen, S., Sailas, E. S., Joutsenniemi, K., Holi, M. M., & Suvisaari, J. (2015) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2014.983544 · Cited by 30
Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study
Veerman, S. R. T., Schulte, P. F. J., Deijen, J. B., & de Haan, L. (2016) · Psychological Medicine · doi:10.1017/s0033291716002476 · Cited by 30
The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders
Pignon, B., du Montcel, C. T., Carton, L., & Pélissolo, A. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0847-x · Cited by 31
Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis
Kishi, T., Ikuta, T., Oya, K., Matsunaga, S., Matsuda, Y., & Iwata, N. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy045 · Cited by 30
Efficacy of typical and atypical antipsychotic medication on hostility in patients with psychosis-spectrum disorders: a review and meta-analysis
Faay, M. D. M., Czobor, P., & Sommer, I. E. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0161-2 · Cited by 30
Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia
Nasrallah, H. A., Aquila, R., Du, Y., Stanford, A. D., Claxton, A., & Weiden, P. J. (2018) · CNS Spectrums · doi:10.1017/s1092852918001104 · Cited by 29
A symptom combination predicting treatment-resistant schizophrenia – A strategy for real-world clinical practice
Ortiz, B. B., Higuchi, C. H., Noto, C. D. S., Joyce, D. W., Correll, C. U., Bressan, R. A., & Gadelha, A. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.01.002 · Cited by 30
The Recent Development of Piperazine and Piperidine Derivatives as Antipsychotic Agents
Rathore, A., Asati, V., Kashaw, S. K., Agarwal, S., Parwani, D., Bhattacharya, S., & Mallick, C. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666200910092327 · Cited by 30
Association between antipsychotic medication and clinically relevant weight change: meta-analysis
Campforts, B. C. M., Drukker, M., Crins, J., van Amelsvoort, T., & Bak, M. (2023) · BJPsych Open · doi:10.1192/bjo.2022.619 · Cited by 32
Factors associated with non evidence-based prescribing of antipsychotics
Connolly, A., & Taylor, D. M. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540298 · Cited by 30
Assessing and Reporting the Adverse Effects of Antipsychotic Medication
Longden, E., & Read, J. (2016) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000117 · Cited by 33
Cariprazine specificity profile in the treatment of acute schizophrenia
Corponi, F., Serretti, A., Montgomery, S., & Fabbri, C. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000189 · Cited by 30
Metabolic syndrome in patients with schizophrenia: Underlying mechanisms and therapeutic approaches (Review)
Manta, A., Georganta, A., Roumpou, A., Zoumpourlis, V., Spandidos, D. A., Rizos, E. N., & Peppa, Μ. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13479 · Cited by 40
Antipsychotic drug exposure and risk of pulmonary embolism: a population-based, nested case–control study
Conti, V., Venegoni, M., Cocci, A., Fortino, I., Lora, A., & Barbui, C. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0479-9 · Cited by 29
Self-citation
Early insulin resistance predicts weight gain and waist circumference increase in first-episode psychosis – A one year follow-up study
Keinänen, J., Mantere, O., Kieseppä, T., Mäntylä, T. J. S., Torniainen, M., Lindgren, M., Sundvall, J., & Suvisaari, J. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.11.002 · Cited by 31
Relapses and recurrences of catatonia: 30-case analysis and literature review
Lin, C.-C., Hung, Y.-Y., Tsai, M.-C., & Huang, T. (2016) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2016.01.011 · Cited by 29
The efficacy of a new translational treatment for persecutory delusions: study protocol for a randomised controlled trial (The Feeling Safe Study)
Freeman, D. H., Waite, F., Emsley, R., Kingdon, D., Davies, L. M., Fitzpatrick, R. M., & Dunn, G. (2016) · Trials · doi:10.1186/s13063-016-1245-0 · Cited by 29
Qualitative systematic review of barriers and facilitators to patient-involved antipsychotic prescribing
Pedley, R., McWilliams, C., Lovell, K., Brooks, H. L., Rushton, K., Drake, R., Rumbold, B., Bell, V., & Bee, P. (2018) · BJPsych Open · doi:10.1192/bjo.2017.5 · Cited by 29
Daily functioning and symptom factors contributing to attitudes toward antipsychotic treatment and treatment adherence in outpatients with schizophrenia spectrum disorders
Leijala, J., Kampman, O., Suvisaari, J., & Eskelinen, S. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03037-0 · Cited by 35
Pharmacotherapy of schizophrenia: Mechanisms of antipsychotic accumulation, therapeutic action and failure
Chestnykh, D., Amato, D., Kornhuber, J., & Müller, C. P. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113144 · Cited by 33
A Case for Thalamic Mechanisms of Schizophrenia: Perspective From Modeling 22q11.2 Deletion Syndrome
Jiang, Y., Patton, M. H., & Zakharenko, S. S. (2021) · Frontiers in Neural Circuits · doi:10.3389/fncir.2021.769969 · Cited by 32
Mechanism and treatments of antipsychotic-induced weight gain
Ye, W., Xing, J., Yu, Z., Hu, X., & Yan, Z. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01291-8 · Cited by 34
An efficient approach to construct benzisothiazol-3(2H)-ones via copper-catalyzed consecutive reaction of 2-halobenzamides and carbon disulfide
Li, T., Yang, L., Ni, K., Shi, Z., Li, F., & Chen, D. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob00819d · Cited by 29
Analysis of drug–endogenous human metabolite similarities in terms of their maximum common substructures
O’Hagan, S., & Kell, D. B. (2017) · Journal of Cheminformatics · doi:10.1186/s13321-017-0198-y · Cited by 26
Efficacy and Acceptability of Cariprazine in Acute Exacerbation of Schizophrenia
Zhao, M., Qin, B., Wang, J., Zhang, Y., Zhao, J., Mao, Y., Zhang, X., & Zhang, R. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000834 · Cited by 29
The validity and sensitivity of PANSS ‐6 in treatment‐resistant schizophrenia
Østergaard, S. D., Foldager, L., Mors, O. N., Bech, P., & Correll, C. U. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12952 · Cited by 30
Clozapine and Psychosocial Function in Schizophrenia: A Systematic Review and Meta-Analysis
Olagunju, A. T., Clark, S. R., & Baune, B. T. (2018) · CNS Drugs · doi:10.1007/s40263-018-0565-x · Cited by 30
Advances in Dopamine D1 Receptor Ligands for Neurotherapeutics
Felsing, D. E., Jain, M. K., & Allen, J. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190712210903 · Cited by 27
Are CB2 Receptors a New Target for Schizophrenia Treatment?
Cortez, I. L., da Silva, N. R., Guimarães, F. S., & Gomes, F. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.587154 · Cited by 29
Effectiveness of long-acting injectable antipsychotics: a clinical perspective
Castillo, E. G., & Stroup, T. S. (2015) · Evidence Based Mental Health · doi:10.1136/eb-2015-102086 · Cited by 28
Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis
Correll, C. U., Højlund, M., Graham, C. E., Todtenkopf, M. S., McDonnell, D., & Simmons, A. (2023) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyad029 · Cited by 30
Olanzapine Pharmacokinetics: A Clinical Review of Current Insights and Remaining Questions
Kolli, P., Kelley, G., Rosales, M., Faden, J., & Serdenes, R. (2023) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s391401 · Cited by 37
The atypical antipsychotics lurasidone and olanzapine exert contrasting effects on the gut microbiome and metabolic function of rats
Kamath, S., Hunter, A., Collins, K., Wignall, A. D., & Joyce, P. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16507 · Cited by 30
Long-term use of antipsychotics among community-dwelling persons with Alzheimer׳s disease: A nationwide register-based study
Koponen, M., Taipale, H. T., Tanskanen, A. J., Tolppanen, A., Tiihonen, J., Ahonen, R. S., & Hartikainen, S. A. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.07.008 · Cited by 28
Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia
Xiang, Y., Ungvari, G. S., Correll, C. U., Chiu, H. F. K., & Shinfuku, N. (2015) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796015000694 · Cited by 28
Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries
Garay, R. P., Citrome, L., Samalin, L., Liu, C., Thomsen, M. S., Correll, C. U., Hameg, A., & Llorca, P. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1149164 · Cited by 30
Increased levels of serum leptin in the early stages of psychosis
Martorell, L., Muntané, G., Porta-López, S., Moreno, I., Ortega, L., Montalvo, I., Sánchez‐Gistau, V., Monseny, R., Labad, J., & Vilella, E. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.01.006 · Cited by 28
Resting-state functional connectivity in treatment response and resistance in schizophrenia: A systematic review
Chan, N. K., Kim, J. N., Shah, P., Brown, E. E., Plitman, E., Caravaggio, F., Iwata, Y., Gerretsen, P., & Graff‐Guerrero, A. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.07.020 · Cited by 28
A systematic review and combined meta‐analysis of concentration of oral amisulpride
Li, L., Li, L., Shang, D., Wen, Y., & Ning, Y. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14246 · Cited by 29
HTR1A, HTR1B, HTR2A, HTR2C and HTR6 Gene Polymorphisms and Extrapyramidal Side Effects in Haloperidol-Treated Patients with Schizophrenia
Grubor, M., Živković, M., Šagud, M., Perković, M. N., Mihaljević-Peleš, A., Pivac, N., Mück‐Šeler, D., & Štrac, D. Š. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072345 · Cited by 27
Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study
Yagoda, S., Graham, C. E., Simmons, A., Arevalo, C., Jiang, Y., & McDonnell, D. (2020) · CNS Spectrums · doi:10.1017/s1092852920001376 · Cited by 28
The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia
Fountoulakis, K. Ν., Moeller, H.-J., Kasper, S. F., Tamminga, C. A., Yamawaki, S., Kahn, R. S., Tandon, R., Correll, C. U., & Javed, A. (2020) · CNS Spectrums · doi:10.1017/s1092852920001546 · Cited by 28
N-Heterocyclic carbene (NHC)-catalyzed intramolecular benzoin condensation–oxidation
Satyam, K., Ramarao, J., & Suresh, S. (2021) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob02606a · Cited by 28
Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder
Lintunen, J., Taipale, H. T., Tanskanen, A. J., Mittendorfer‐Rutz, E., Tiihonen, J., & Lähteenvuo, M. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab004 · Cited by 32
Effect of alpha-mangostin on olanzapine-induced metabolic disorders in rats.
Ardakanian, A., Rahbardar, M. G., Omidkhoda, S. F., Razavi, B. M., & Hosseinzadeh, H. (2022) · PubMed Central · doi:10.22038/ijbms.2022.58734.13047 · Cited by 28
Modulation of hypothalamic AMPK phosphorylation by olanzapine controls energy balance and body weight
Ferreira, V., Folgueira, C., Guillén, M., Zubiaur, P., Navares, M., Sarsenbayeva, A., López-Larrubia, P., Eriksson, J. W., Pereira, M. J., Abad‐Santos, F., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155335 · Cited by 29
Effectiveness and Predictors of Continuation of Paliperidone Palmitate Long-Acting Injection Treatment
Whale, R., Pereira, M., Cuthbert, S., & Fialho, R. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000385 · Cited by 28
Network Meta-analysis: Users’ Guide for Surgeons: Part II - Certainty
Chaudhry, H., Foote, C. J., Guyatt, G. H., Thabane, L., Furukawa, T. A., Petrisor, B. A., & Bhandari, M. (2015) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-015-4287-9 · Cited by 28
Drug-induced parkinsonism: diagnosis and management
Blanchet, P. J., & Kivenko, V. (2016) · Journal of Parkinsonism and Restless Legs Syndrome · doi:10.2147/jprls.s99197 · Cited by 28
Effectiveness of antipsychotics used in first-episode psychosis: a naturalistic cohort study
Whale, R., Harris, M., Kavanagh, G., Wickramasinghe, V., Jones, C. I., Marwaha, S., Jethwa, K. D., Ayadurai, N., & Thompson, A. D. (2016) · BJPsych Open · doi:10.1192/bjpo.bp.116.002766 · Cited by 29
Pharmacoinformatics and molecular docking studies reveal potential novel Proline Dehydrogenase (PRODH) compounds for Schizophrenia inhibition
Sehgal, S. A. (2016) · Medicinal Chemistry Research · doi:10.1007/s00044-016-1752-2 · Cited by 28
Effects of cannabis use on body mass, fasting glucose and lipids during the first 12 months of treatment in schizophrenia spectrum disorders
Scheffler, F., Kilian, S., Chiliza, B., Asmal, L., Phahladira, L. S., du Plessis, S., Kidd, M., Murray, R. M., Forti, M. D., Seedat, S., et al. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.02.050 · Cited by 28
Analysis of Clozapine Use and Safety by Using Comprehensive National Data From the Japanese Clozapine Patient Monitoring Service
Inada, K., Oshibuchi, H., Ishigooka, J., & Nishimura, K. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000904 · Cited by 28

Authors: Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., Kissling, W., Stapf, M. P., Lässig, B., Salanti, G., & Davis, J. M.
Affiliations: TUM Klinikum (DE)
University of Verona (IT)
University of Ioannina (GR)
Ludwig-Maximilians-Universität München (DE)
Warneford Hospital (GB)
University of Illinois Chicago (US)
Corresponding author: Leucht, Stefan
ORCID: Leucht, Stefan
Cipriani, Andrea
Spineli, Loukia
Mavridis, Dimitris
Samara, Myrto
Barbui, Corrado
Engel, Rolf R
Geddes, John R
Salanti, Georgia
Davis, John M
Venue: The Lancet
Publisher: Elsevier BV
Published: 2013-09
Volume: 382
Issue: 9896
Pages: 951-962
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(13)60733-3
OpenAlex: W2009832071
Cited by: 2,561
References: 61
Citations by year: 2026: 134 · 2025: 135 · 2024: 161 · 2023: 146 · 2022: 182 · 2021: 215 · 2020: 223 · 2019: 221 · 2018: 217 · 2017: 228 · 2016: 255 · 2015: 243 · 2014: 160 · 2013: 36
FWCI: 164.63
Type: journal article
Language: en
Open access: closed
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Funders: National Institute for Health and Care Research (NF-SI-0611-10150)
H. Lundbeck A/S
Medical Research Council
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: schizophrenia, antipsychotic drugs, drug efficacy comparison, tolerability, Bayesian framework, weight gain, extrapyramidal symptoms, QTc prolongation, sedation, clozapine, amisulpride, olanzapine, risperidone, paliperidone, zotepine
MeSH terms: Adult, Humans, Schizophrenia, Antipsychotic Agents, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks